Several of these HDACinhibitors inhibit tumour growth and many of them are under clinical trials (11,12).The approval of SAHA (Zolinza®, Vorinostat) by the FDA for treatment of advanced cutaneous T-cell lymphoma (CTCL) has added histone deacetylase(HDAC) inhibitors to the clinician‘s armoury of anti-cancer therapeutics (13). The gene discussed is HDAC9; the disease is neoplasm.